Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study to Explore the Efficacy and Feasibility of Upfront Bi-monthly Rotations Between Everolimus and Pazopanib in Patients With Advanced or Metastatic Clear Cell Renal Cancer

NCT01408004 is registered in ClinicalTrials.gov with Netherlands Working Group on Immunotherapy of Oncology as lead sponsor.

NCT NCT01408004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01408004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study to Explore the Efficacy and Feasibility of Upfront Bi-monthly Rotations Between Everolimus and Pazopanib in Patients With Advanced or Metastatic Clear Cell Renal Cancer
Lead sponsor
Netherlands Working Group on Immunotherapy of Oncology
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
April 30, 2014
Enrollment
101 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal carcinoma